Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atazanavir/cobicistat - Bristol-Myers Squibb/Gilead

Drug Profile

Atazanavir/cobicistat - Bristol-Myers Squibb/Gilead

Alternative Names: Atazanavir sulfate/cobicistat; ATV/GS9350; Evotaz

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences
  • Class Antiretrovirals; Carbamates; Morpholines; Oligopeptides; Pyridines; Small molecules; Thiazoles; Urea compounds
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 11 Feb 2022 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (PO, Tablet) in February 2022 (NCT05236738)
  • 09 Sep 2021 Bristol-Myers Squibb completes a phase I trial for Healthy volunteers in USA (PO) (NCT02307656)
  • 20 May 2021 Preregistration for HIV-1 infections (Combination therapy, In adolescents, In adults) in European Union (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top